Overview

A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone

Status:
Recruiting
Trial end date:
2025-08-20
Target enrollment:
Participant gender:
Summary
One of the most frequent skin conditions is atopic dermatitis (AD), characterized by its pruritic inflammation effect. Where the prevalence of AD increased in the last three decades by two or three folds worldwide, especially in developed countries, AD is supposed to affect about 15% to 30% of children, and 2% to 10% of adults. This type of dermatitis is frequently linked to a family history of other atopic illnesses such as allergic rhinitis or asthma.
Phase:
Phase 2
Details
Lead Sponsor:
Tanta University
Treatments:
Hydrocortisone
Tacrolimus